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This is a case report on a giant cell tumor of the jux-
ta-articular proximal tibia with a pathological fracture. A 
female patient presented pain and increased local volume 
after falling from her own height. She underwent clini-
cal examination, radiographic examination and puncture 
biopsy. A diagnosis of giant cell tumor was made. The 
patient was then treated with tumor resection and use 
of an unconventional partial endoprosthesis of the tibia 
with preservation of the joint surface of the tibial plate-
au. The patient evolved with improvement of symptoms 
and maintenance of joint function of the operated limb, 
absence of recurrence and complications, without any 
need for reoperation over 18 years of follow-up. 
Keywords – Giant Cell Tumors; Tibia; Knee; Prostheses 
and Implants
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Giant cell tumors are aggressive benign tumors with 
vascularized tissue and the presence of fusiform or 
ovoid cells, and characterized by the presence of giant 
osteoclastic cells(1). They were initially described by 
Sir Astley Cooper(2) and were named brown tumors by 
Paget(3). Bloodgood(4) was the author who defined them 
as benign giant cell tumors. According to Geschikter and 
Copeland(5) and Willis(6), giant cell tumors are neoplas-
ms of osteoclasts surrounded by mesenchymal stroma, 
because of the similarity between the giant cell and non-
neoplastic osteoclasts. Jaffe et al(7) described their origin 
as derived from stroma cells, and this hypothesis was 
corroborated by Schajowics(8), through histochemical 
analysis and cell cultures, thereby confirming that there 
were no significant differences between tumor osteo-
clasts and normal osteoclasts.
The anatomopathological grade is given by the stro-
ma and not by the giant cells themselves, which may be 
present in other tumoral or pseudotumoral lesions, such 
as brown tumors, aneurysmatic bone cysts, epiphyseal 
chondroblastoma, osteoblastoma and non-osteogenic 
fibroma(9).
These tumors usually affect patients aged between 20 
and 40 years, i.e. generally with the growth plate closed. 
The incidence of giant cell tumors within the age group 
up to 15 years is 1.7% among the cases of this pathologi-
cal condition. Other studies have demonstrated an inci-
dence of around 0.8% for cases of metaphyseal giant cell 
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tumors in patients with an open growth plate(10). These 
tumors affect both sexes with similar frequency(11,12). 
They mainly develop in the epiphyseal-metaphyseal 
region, and are most frequent in the distal epiphysis of 
the femur (28.2%) and the proximal epiphysis of the 
tibia(13,14). Only 5% occur in flat bones; the sacrum is the 
commonest site of occurrence in the axial skeleton and 
may give rise to neurological manifestations(1,15). 
These are tumors of puffy appearance, generally 
rounded or oval-shaped, and are distributed eccentri-
cally. They may destroy the epiphyseal and joint re-
gions, although the joint cartilage usually tends to be 
spared. Occurrences of fractures in the cortical bone of 
the segment affected is common, and are most frequent 
in the distal femur(16). Because these are epiphyseal tu-
mors, joint impairment with functional abnormalities 
and joint effusion may be present, thereby simulating 
meniscal-ligamentous or arthritic processes(14,17). The 
main symptoms are local pain and increased volume, 
and the start of the clinical history generally correlates 
with a traumatic event(18,19). 
Metastases occur in around 1% of the cases, espe-
cially to the lungs(20). They are non-aggressive and have 
been correlated with multiple manipulations and local 
recurrence.
The aim of this study was to report on a case of 
giant cell tumor in the proximal epiphysis of the tibia, 
with a pathological fracture, in which an unconventional 
endoprosthesis was used, thereby preserving the joint 
surface of the tibial plateau, with gratifying long-term 
functional, esthetic and clinical results.
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This was a 17-year-old female patient who presented 
pain and progressively increasing volume of the anterior 
region of the right proximal tibia that had been evolving 
for five months. After falling from her own height, she 
presented comminution of the anterior cortical bone on 
radiological examination, which was treated in another 
clinic with plaster-cast immobilization from the groin to 
the foot. She was then referred to the Orthopedic Sur-
gery Service of Hospital Erasto Gaertner for evaluation. 
Upon physical examination, visible and palpable tumor 
development was noted in the anterior region of the right 
proximal tibia, with pain and functional impotence of 
the right knee. 
Radiographic examination (Figures 1A and B) de-
monstrated an epiphyseal-metaphyseal lesion one cen-
timeter from the joint surface of the knee, extending 
distally for 15 centimeters in the direction of the me-
taphysis. It had a puffy, rounded appearance, tapering 
onto the cortical bone in an eccentric manner, and with 
comminution of the anterior cortex in the middle third 
of the lesion. The patient was restricted to bed at that 
time.
It was proposed to perform a closed biopsy with the 
use of a trephine, in order to obtain diagnostic con-
firmation of the lesion. From the anatomopathological 
examination, a giant cell tumor was diagnosed (Figure 
1C). In the light of these findings, the patient’s youth 
and the aggressive nature of the tumor, it was decided to 
resect the bone segment that contained the tumor, while 
preserving the joint surface of the knee, with placement 
of an unconventional endoprosthesis for the proximal 
tibia (Figure 2A). The patient underwent intravenous an-
tibiotic therapy during the induction phase of the anes-
thesia. Then, after performing antisepsis on the skin, 
the tumor was approached by means of a longitudinal 
anterior incision in the knee. The bone segment affected 
was resected, while preserving the extensor mechanism. 
Following this, the diaphyseal medullary canal was pre-
pared with the use of progressively larger milling tools, 
in order to adapt the nail to the bone. After this first 
phase, the prosthesis was adapted proximally below the 
surface of the tibial plateau and was fixed using spongy 
screws. While closing the anatomic planes, a vacuum 
drain was inserted. During the postoperative period, the 
patient was kept without the use of orthoses, and she 
made an early start to assisted isometric exercises. The 
leg was released for load-bearing after the tenth week, 
with the aid of crutches. 
The endoprosthesis used was developed and manu-
factured from titanium and polyethylene in the bioen-
gineering laboratory of Hospital Erasto Gaertner within 
the same year (Figure 2). Its dimensions were, for the 
&IGURE  – A) Preoperative radiograph: frontal view showing puffy 
lesion with comminution of the anterior cortical bone in the pro-
ximal third of the right tibia. B) Preoperative radiograph in lateral 
view. C) Image of the lamina showing giant cell surrounded by 
mesenchymal stroma.
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titanium GR.S Ø 19.10 mm and, for the polyethylene, 
GR.S Ø 10 mm.
Today, the patient presents full performance in her 
work activities (in the home), while reporting occasional 
pain when carrying out walking activities for prolonged 
periods or doing endurance exercises (Figures 3A, B and 
C). She currently presents a discrepancy, measured by 
means of scanometry (Table 1).
Radiographic evaluation on the operated knee showed 
preservation of the joint relations, absence of arthrotic 
abnormalities and absence of remarkable features in the 
soft tissues. The same characteristics were observed in 
the non-operated limb (Figure 4) (Figures 2B and C).
Control computed tomography on the lower limbs 
was also performed, and this showed bone deminerali-
zation in the operated femur, but with preserved joint 
relations and without evidence of tumor recurrence. 
The left knee presented bone elements with normal 
shape and structure, and lateralization of the patella
(Figures 5A and B).
&IGURE  – A) Immediate postoperative period: radiographs in frontal and lateral views (May 1991). B) Control radiograph in frontal 
view after 18 years of follow-up (May 2009). C) Control radiograph in lateral view after 18 years of follow-up.
Figure 3 – Current assessment, 18 years after the operation: A) 
Standing on two feet in frontal view. B) Standing on two feet in 
lateral view. C) Standing on one foot with flexion of the operated 
limb. D) Patient in squatting position.
Figure 4 – Original design for the prosthesis used, which was 
developed and manufactured in the Bioengineering Laboratory 
of Hospital Erasto Gaertner, 1990.
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3CANOMETRY MEASUREMENTS 
Right femur 47.00 cm  
Left femur 47.00 cm 
Right tibia 38.50 cm 
Left tibia 38.75 cm 
Right lower limb 85.50 cm 
Left lower limb 85.75 cm 
4ABLE  – Scanometry on lower limbs.
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The physiotherapeutic evaluation consisted of as-
sessing the pain, analyzing the gait and making an an-
thropometric evaluation. A visual analogue scale was 
applied with the aim of quantifying the intensity of this 
pain. The patient graded her pain as six, thus classifying 
it as moderate, which hindered her activities but did not 
impede them (Table 2).
The visual analogue scale(21) consists of an aid for 
measuring the intensity of patients’ pain. It is an impor-
tant instrument for monitoring patients’ evolution over 
the course of their treatment, and even at each consul-
tation, in a more faithful manner. It is also useful for 
enabling analysis on whether the treatment is having 
any effect, which procedures are having the best results 
and whether there are any deficiencies in the treatment, 
according to the degree of improvement or worsening 
of the pain.
The visual analogue scale can be used at the start 
and end of each attendance session, to register the re-
sultant evolution. To use the visual analogue scale, the 
attending professional should ask the patient about the 
degree of pain felt, such that 0 signifies total absence 
of pain and 10 is the maximum level of pain that the 
patient can tolerate.
With regard to gait, a visual analysis was made, in 
which the patient presented steps of longer duration and 
slower speed, although all the phases of gait were pre-
sent. It cannot be said precisely whether these changes 
were due to the prosthesis or whether they were due 
to the gait pattern of obese individuals, given that this 
patient presented a body mass index greater than 32.
The patient underwent anthropometric analyses by 
Figure 5 – A) Tomographic images of the right and left distal 
femur. B) Tomographic image of the right and left proximal tibia: 
postoperative, with 18 years of evolution.
means of a pachymeter and measuring tape (Table 3), 
which showed minimal trophic alterations registered in 
the lower limbs.
The range of motion on the operated side consisted of 
painless flexion-extension 150-0, which was measured 
with the aid of a goniometer.
$)3#533)/.
The bases for treating giant cell tumors are the site 
of occurrence, extent of the lesion and degree of tumor 
aggressiveness.
Complete bone resection may be performed in some 
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   3 4 5 6   9 
No pain Slight pain Moderate pain Strong or incapacitating pain Intolerable pain
Does not hinder activities Hinders activities but does not impede them Impedes activities
Impedes activities and 
causes lack of control
4ABLE  – Visual analogue scale.
Height 165.7
Body mass 90.5
Width between the iliac spines 24
Right Left
Impairment in thigh 
(greater trochanter and femoral condyle)
43.5 42.5
Mid-thigh circumference 64.3 66
Lower leg length (epicondyle to lateral malleolus) 41.5 42
Lower leg circumference (region with greatest volume) 39.5 39
Knee diameter 12.7 11.3
Length of foot 25.4 25.5
Height of malleolus (from lateral malleolus to the ground) 6 6
Diameter of the malleolus (lateral and medial malleolus) 6.7 6.5
Width of foot (widest part of foot) 10.4 10.1
4ABLE    – Body measurements for evaluation of trophic ab-
normalities.
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cases without severe functional harm to the patient, such 
as in cases involving the ulna, fibula and small bones of 
the hand and foot. The incidence of tumor recurrence 
is related to the type of treatment undertaken, and it 
is greater in cases treated with curettage, with or wi-
thout associated use of bone grafting(22,23). Curettage 
should be accompanied by local adjuvant treatment, in 
an attempt to avoid survival of remaining cells(10). Cur-
rent treatment methods for some lesions that are non-
aggressive and in favorable locations include the use 
of methyl methacrylate, cryotherapy, electrocauteriza-
tion, phenol and alcohol. In cases of aggressive lesions, 
with more accentuated bone destruction, the alternatives 
may include amputation proximal to the lesion, which 
is indicated for lesions of an advanced nature, cases 
presenting infection or cases that are undergoing ma-
lignant transformation. However, more usually, en-bloc 
resection is performed, with reconstruction by means 
of unconventional endoprostheses or biological recons-
truction using grafts (autologous and/or homologous) or 
bone transportation. Radiotherapy has been proscribed 
because of the risk of malignant transformation during 
the treatment of these lesions, and embolization may 
be used for tumors that are shown to have abundant or 
non-resectable vascularization(1). 
Reconstruction of the segment after lesion resection 
has been based on the radiographic staging proposed by 
Campanacci et al(24,25).
1 – Quiescent or intraosseous lesion;
2 – Active lesion with intact periosteum;
3 – Aggressive lesion, with destruction of the perios-
teum and invasion of the soft tissues.
In type I lesions, curettage can be performed in isola-
tion from the lesion, although there may be recurrences. 
In type 2 and 3 lesions, complete resection of the lesion 
is indicated. Among the various ways of reconstructing 
the segment from which the tumoral lesion was resec-
ted, the main methods used are autografts, homografts, 
arthrodesis and unconventional endoprostheses.
The use of autografts is reserved for reconstruction 
of small defects within the treatment for quiescent and 
intraosseous tumors (Campanacci grade 1). Homograf-
ting techniques, with the use of grafts from a bone bank, 
have their place in cases of en-bloc resection, for cases 
with severely compromised joint surface. Arthrodesis, 
with the use of synthesis materials and some types of 
graft, can be performed in the presence of current infec-
tion or when the use of endoprostheses is impossible, 
particularly in cases of younger patients with greater 
physical demands and favorable life expectancy. The use 
of non-conventional endoprostheses has been described 
for reconstruction of large resected bone segments. Ho-
wever, because this is a benign neoplasm, some authors 
have preferred to use reconstruction methods that are 
more biological in nature for treating these lesions, and 
have emphasized the disadvantage of successive chan-
ges of prosthesis, which are expected particularly among 
affected patients in younger age groups, and because of 
the long survival presented by these patients(1).
According to Cassone et al(26), the reconstruction me-
thods used after performing en-bloc resection of the pro-
ximal tibia encompass three basic problems: the major 
bone loss, the instability of the knee and the loss of the 
extensor mechanism. These authors stated that the main 
complications found were of mechanical and infectious 
nature. From a mechanical point of view, wear on the 
polyethylene and breakage due to weakness of the nail 
of the tibial component occur at low rates because the 
nail in the tibia coincides with the mechanical and ana-
tomical axes of the limb, thereby reducing the stress.
MacDonald et al(27) reported that pathological frac-
tures did not increase the chances of tumor recurrence. 
O’Donnell et al(28) and Renard et al(29) concluded that 
there was a correlation between occurrences of patho-
logical fractures and tumor recurrence. Garcia Filho et 
al
(1) postulated that perhaps the fracture would make the 
surgical approach more difficult and make the curettage 
less effective. They did not observe any relationship 
between tumor occurrences and pathological fractures 
with joint invasion, in cases of giant cell tumor. 
The patient with a giant cell tumor of the present 
report had an active giant cell tumor and an intact pe-
riosteum. She had suffered a pathological fracture due to 
a fall from her own height, which resulted in worsened 
pain and functional impotence with regard to walking. 
It was decided to preserve the patient’s joint surface by 
means of segmental resection and the use of an uncon-
ventional endoprosthesis for the proximal tibia because 
of her youth, the longevity observed among patients 
with this type of tumor and the possibility of successi-
ve surgical interventions to which the patient would be 
subjected if an endoprosthesis replacing the knee joint 
surface were to be implanted. The use of simple curet-
tage and autografting were dismissed because of the 
extent and aggressiveness presented by the tumor, and 
the use of homografting was not available at our clinic 
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at the time of the treatment that was implemented.
The patient now has few painful symptoms, satis-
factory knee joint functional levels, range of motion 
within the limits of normality, without manual work 
limits (housework) without limits on activities of daily 
living. She has not presented any clinical or radiological 
evidence (radiographs and axial computed tomography 
scans) of tumor recurrence, and she remains without any 
need for surgical revision at present. The use of a partial 
cementless endoprosthesis for the tibia that preserved 
the knee joint was shown to have gratifying long-term 
clinical, radiological, functional and esthetic results.
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